| Original language | English (US) |
|---|---|
| Pages (from-to) | 1020 |
| Number of pages | 1 |
| Journal | Neurology |
| Volume | 77 |
| Issue number | 10 |
| DOIs | |
| State | Published - Sep 6 2011 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Neurology, Vol. 77, No. 10, 06.09.2011, p. 1020.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS
AU - Ko, Michael Y.
AU - Stefoski, Dusan
AU - Balabanov, Roumen
N1 - Funding Information: Disclosure: Dr. Vennegoor has received research support through his institution from Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, and Teva Pharmaceutical Industries Ltd. Dr. Wattjes has received speaker honoraria from Janssen, Bayer Schering Pharma, and Biogen Idec; and has received research support through his institution from UCB, Merck Serono, and Novartis. Dr. van Munster has received research support through his institution from Biogen Idec, Teva Pharmaceutical Industries Ltd., Merck Serono, and GlaxoSmithKline; and has served on a scientific advisory board or consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Merck Serono, and Novartis. Dr. Kriekaart has received research support through his institution from Biogen Idec, Teva Pharmaceutical Industries Ltd., Merck Serono, and GlaxoSmithKline; and has served as a consultant for Biogen Idec. Dr. van Oosten has received research support through his institution from Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, and Teva Pharmaceutical Industries Ltd. Dr. Barkhof serves on scientific advisory boards for Lundbeck Inc., Bayer Schering Pharma, sanofi-aventis, UCB, Novartis, Biogen Idec, BioMS Medical, Merck Serono, and GE Healthcare; serves on the editorial boards of Brain, the Journal of Neurology, Neurosurgery, and Psychiatry, European Radiology, the Journal of Neurology, and Neuroradiology; has received speaker honoraria from Novartis and Merck Serono; serves as a consultant for sanofi-aventis, UCB, Novartis, Biogen Idec, BioMS Medical, and Medicinova, Inc.; and receives research support from the Dutch MS Research Foundation. Dr. Killestein serves on scientific advisory boards for Novartis and Merck Serono; serves on the editorial board of Multiple Sclerosis International; serves as a consultant for Merck Serono; has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Genzyme Corporation, and Novartis. Dr. Polman serves on scientific advisory boards for Actelion Pharmaceuticals Ltd, Biogen Idec, Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., Merck Serono, GlaxoSmithKline, UCB, Roche, and Antisense Therapeutics Limited; serves on the editorial boards of Lancet Neurology and Multiple Sclerosis; has received speaker honoraria from Biogen Idec, Bayer Schering Pharma, Novartis, and Teva Pharmaceutical Industries Ltd.; and receives research support from Biogen Idec, Bayer Schering Pharma, GlaxoSmithKline, Novartis, UCB, Merck Serono, Teva Pharmaceutical Industries Ltd., the European Community (EEC), and from the Dutch Multiple Sclerosis Society.
PY - 2011/9/6
Y1 - 2011/9/6
UR - http://www.scopus.com/inward/record.url?scp=80055075156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055075156&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31822946d0
DO - 10.1212/WNL.0b013e31822946d0
M3 - Letter
C2 - 21893676
AN - SCOPUS:80055075156
SN - 0028-3878
VL - 77
SP - 1020
JO - Neurology
JF - Neurology
IS - 10
ER -